MX2023008651A - Forma cristalina de 6-(ciclopropanocarboxamido)-4-((2-metoxi-3-(1- metil-1h-1,2,4-triazol-3-il)fenil)amino)-n-(metil-d3)piridazina-3 -carboxamida. - Google Patents

Forma cristalina de 6-(ciclopropanocarboxamido)-4-((2-metoxi-3-(1- metil-1h-1,2,4-triazol-3-il)fenil)amino)-n-(metil-d3)piridazina-3 -carboxamida.

Info

Publication number
MX2023008651A
MX2023008651A MX2023008651A MX2023008651A MX2023008651A MX 2023008651 A MX2023008651 A MX 2023008651A MX 2023008651 A MX2023008651 A MX 2023008651A MX 2023008651 A MX2023008651 A MX 2023008651A MX 2023008651 A MX2023008651 A MX 2023008651A
Authority
MX
Mexico
Prior art keywords
methyl
cyclopropanecarboxamido
triazol
pyridazine
carboxamide
Prior art date
Application number
MX2023008651A
Other languages
English (en)
Spanish (es)
Inventor
Victor W Rosso
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=80447586&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2023008651(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2023008651A publication Critical patent/MX2023008651A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2023008651A 2021-01-29 2022-01-28 Forma cristalina de 6-(ciclopropanocarboxamido)-4-((2-metoxi-3-(1- metil-1h-1,2,4-triazol-3-il)fenil)amino)-n-(metil-d3)piridazina-3 -carboxamida. MX2023008651A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163143769P 2021-01-29 2021-01-29
PCT/US2022/014261 WO2022165141A1 (en) 2021-01-29 2022-01-28 Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide

Publications (1)

Publication Number Publication Date
MX2023008651A true MX2023008651A (es) 2023-08-01

Family

ID=80447586

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008651A MX2023008651A (es) 2021-01-29 2022-01-28 Forma cristalina de 6-(ciclopropanocarboxamido)-4-((2-metoxi-3-(1- metil-1h-1,2,4-triazol-3-il)fenil)amino)-n-(metil-d3)piridazina-3 -carboxamida.

Country Status (11)

Country Link
US (2) US12129245B2 (https=)
EP (1) EP4284796B1 (https=)
JP (1) JP2024505063A (https=)
KR (1) KR20230137962A (https=)
CN (1) CN116829549A (https=)
AU (1) AU2022214313A1 (https=)
CA (1) CA3206254A1 (https=)
ES (1) ES3026120T3 (https=)
IL (1) IL304597A (https=)
MX (1) MX2023008651A (https=)
WO (1) WO2022165141A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7113023B2 (ja) * 2017-03-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法
EP4387968B1 (en) * 2021-08-20 2025-11-12 Bristol-Myers Squibb Company Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
EP4423086A1 (en) 2021-10-25 2024-09-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
CN116574056A (zh) * 2023-04-10 2023-08-11 五邑大学 一种氟代异喹啉酮类化合物的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3495358T (lt) * 2012-11-08 2022-05-25 Bristol-Myers Squibb Company Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai
JP7113023B2 (ja) * 2017-03-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法
KR102848769B1 (ko) * 2018-05-31 2025-08-20 브리스톨-마이어스 스큅 컴퍼니 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3) 피리다진-3-카르복스아미드의 결정질 형태
US12570637B2 (en) * 2019-06-12 2026-03-10 Bristol-Myers Squibb Company Crystalline salt forms 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyld3) pyridazine-3-carboxamide

Also Published As

Publication number Publication date
US20250154132A1 (en) 2025-05-15
US12129245B2 (en) 2024-10-29
ES3026120T3 (en) 2025-06-10
JP2024505063A (ja) 2024-02-02
IL304597A (en) 2023-09-01
EP4284796B1 (en) 2025-04-16
KR20230137962A (ko) 2023-10-05
CA3206254A1 (en) 2022-08-04
WO2022165141A1 (en) 2022-08-04
CN116829549A (zh) 2023-09-29
US20220259183A1 (en) 2022-08-18
AU2022214313A1 (en) 2023-08-17
EP4284796A1 (en) 2023-12-06

Similar Documents

Publication Publication Date Title
MX2023008651A (es) Forma cristalina de 6-(ciclopropanocarboxamido)-4-((2-metoxi-3-(1- metil-1h-1,2,4-triazol-3-il)fenil)amino)-n-(metil-d3)piridazina-3 -carboxamida.
MX2022010496A (es) Forma cristalina de 6-(ciclopropanocarboxamido)-4-((2-metoxi-3- (1-metil-1h-1,2,4-triazol-3-il)fenil)amino)-n-(metil-d3) piridazin-3-carboxamida.
AU2022214313A9 (en) Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
PH12022551424A1 (en) Kras g12c inhibitors.
NZ611654A (en) Treatment of jak2-mediated conditions
RU2392275C2 (ru) Бензамидные производные и их применение в качестве активирующих глюкокиназу агентов
MY128664A (en) Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
NZ616298A (en) Aryl-or heteroaryl-substituted benzene compounds
MXPA05011666A (es) Compuestos de pirazol-amida aril-sustituidos utiles como inhibidores de cinasa.
IL199403A0 (en) 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl)phenyl]-1h-pyrazol-5-yl}carbamoyl)-amino]-3-fluorophenoxy}-n-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer
WO2010115836A4 (en) Substituted piperidines as ccr3 antagonists
RU2018122662A (ru) Производное акриланилида, способ его получения и его применения в фармакологии
CA2605854A1 (en) Novel pyridine derivative and pyrimidine derivative (3)
RU2005102098A (ru) Амидное производное
IL269710B2 (en) 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in cancer therapy
CA2601508A1 (en) Cyclopropanecarboxamide derivatives
PH12021550182A1 (en) Crystal form of lanosterol prodrug compound and application thereof
JOP20210227A1 (ar) شكل بلوري من مونوهيدرات 1-(1-أوكسو-1، 2-داي هيدروأيزوكينولين-5-يل)-5-(تراي فلوروميثيل)-n-(2-(تراي فلوروميثيل)بيريدين-4-يل)-1h-بيرازول-4-كربوكساميد
MX2023005447A (es) Inhibidor de sales sólidas cristalinas de meglumina de bcl y métodos de elaboración y uso de estos.
CO2022001450A2 (es) Sal y formas cristalinas de un inhibidor de la cinasa similar a un receptor de activina
CA2526989A1 (en) Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors
PH12018502697A1 (en) Aliphatic prolinamide derivatives
MX392422B (es) Derivados de prolinamida heterociclica
WO2022093610A8 (en) Crystalline 5-(dimethylamino)-n-(4-(morpholinomethyl)phenyl) naphthalene-1-sulfonamide di-hydrochloride di-hydrate
NO963463L (no) Middel for profylakse og behandling av tromboksan A2-medierte sykdommer